Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00157560 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00157560: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT00157560 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00157560, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
Over the last few years several novel agents have been defined which are active in the treatment of relapsed epithelial ovarian carcinoma. Many of these new agents seemed to have mechanisms of action that are different from Carboplatin and taxol. This trial looks to evaluate the effectiveness and toxicity of three sequential chemotherapy doublets in the treatment of women with newly diagnosed ovarian, primary peritoneal or tubal carcinoma.
Interventions
- DRUG Chemotherapy, multiple agents
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2000-12 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00157560
The ClinicalTrials.gov registry entry for NCT00157560 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Chemotherapy, multiple agents is the first listed.
NCT00157560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00157560 about?
NCT00157560 is a clinical study titled "Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma". Over the last few years several novel agents have been defined which are active in the treatment of relapsed epithelial ovarian carcinoma. Many of these new agents seemed to have mechanisms of action that are different from Carboplatin and taxol. This trial looks to evaluate the effectiveness and to...
What is the current status of trial NCT00157560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2000-12. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00157560?
The interventions under investigation include: Chemotherapy, multiple agents (DRUG).
Who is sponsoring clinical trial NCT00157560?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.